Suven Life Sciences Ltd Stock Price Today (NSE: SUVEN)
Suven Life Sciences Ltd
Fundamental Score
Suven Life Sciences Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Suven Life Sciences Ltd share price today is ₹262.75, down 2.63% on NSE/BSE as of 17 June 2026. Suven Life Sciences Ltd (SUVEN) is a Small-cap company in the Healthcare Research, Analytics & Technology sector with a market capitalisation of ₹3.93K (Cr). The 52-week high for SUVEN share price is ₹299.99 and the 52-week low is ₹124.11. The company has a Return on Equity (ROE) of -87.22% and a debt-to-equity ratio of 0.00.
Suven Life Sciences Ltd Share Price Chart — NSE/BSE Historical Performance
Suven Life Sciences Ltd share price chart: 25.59% return over the past month. 52-week high ₹299.99, 52-week low ₹124.11.
Suven Life Sciences Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹275.05 | ₹289.30 | ₹266.85 | ₹275.20 | 27.66L (Cr) | |
| ₹297.95 | ₹297.95 | ₹273.50 | ₹274.85 | 17.20L (Cr) | |
| ₹269.90 | ₹291.34 | ₹269.76 | ₹279.34 | 22.98L (Cr) | |
| ₹267.15 | ₹267.15 | ₹267.15 | ₹267.15 | 0.00 (Cr) | |
| ₹273.80 | ₹277.50 | ₹264.07 | ₹267.15 | 7.78L (Cr) | |
| ₹273.00 | ₹294.88 | ₹271.40 | ₹273.93 | 28.19L (Cr) | |
| ₹270.75 | ₹275.80 | ₹265.00 | ₹271.04 | 8.47L (Cr) | |
| ₹272.00 | ₹274.59 | ₹259.70 | ₹265.45 | 7.81L (Cr) | |
| ₹266.11 | ₹277.00 | ₹265.21 | ₹269.52 | 11.68L (Cr) | |
| ₹263.30 | ₹277.99 | ₹263.30 | ₹268.98 | 30.53L (Cr) |
Suven Life Sciences Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹297.95 | ₹297.95 | ₹266.85 | ₹275.20 | -7.64% | |
| ₹211.84 | ₹294.88 | ₹200.00 | ₹279.34 | +31.86% | |
| ₹139.50 | ₹229.69 | ₹135.50 | ₹211.88 | +51.89% | |
| ₹140.00 | ₹148.00 | ₹124.11 | ₹131.70 | -5.93% | |
| ₹139.90 | ₹176.02 | ₹131.63 | ₹146.07 | +4.41% | |
| ₹166.50 | ₹178.50 | ₹125.45 | ₹132.81 | -20.23% | |
| ₹172.50 | ₹183.80 | ₹160.20 | ₹166.27 | -3.61% | |
| ₹198.37 | ₹207.01 | ₹166.55 | ₹172.14 | -13.22% | |
| ₹204.21 | ₹216.79 | ₹186.00 | ₹197.55 | -3.26% | |
| ₹209.00 | ₹235.67 | ₹200.00 | ₹204.21 | -2.29% | |
| ₹275.60 | ₹278.00 | ₹208.00 | ₹213.95 | -22.37% | |
| ₹246.15 | ₹299.99 | ₹240.00 | ₹272.37 | +10.65% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Suven Life Sciences Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Suven Life Sciences Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SUVEN across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (67.36%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
12 factors identified
Below-Average Return on Equity (-87.22%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-86.96%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-1086.16%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Profit Decline Concern (-55.74%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-64.20%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-12.00% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-14.08% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-24.19% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (-21188.00x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-672.93 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 4.56%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Suven Life Sciences Ltd vs Healthcare Research, Analytics & Technology Peers
Peer Comparison - Healthcare Research, Analytics & Technology
Compare Suven Life Sciences Ltd with 8 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Suven Life Sciences LtdSuven Life Scie...Selected✓ SUVEN • 530239 | 6.5/100 | ₹262.75₹263 | ₹3927.58₹3927.58 | — — | -87.22%Poor -87.22% Poor | -86.96%Poor -86.96% Poor | 0.00Excellent 0.0 Excellent | -24.19%Poor -24.19% Poor | -12.00%Poor -12.00% Poor | 0.00% |
Syngene International LtdSyngene Interna... SYNGENE • 539268 | 41.6/100 | ₹460.40₹460 | ₹25985.68₹25985.68 | 55.50Average 55.5 Average | 10.53%Average 10.53% Average | 13.52%Average 13.52% Average | 0.12Excellent 0.1 Excellent | 5.71%Good 5.71% Good | 12.60%Good 12.60% Good | 0.19% |
Indegene LtdIndegene Ltd... INDGN • 544172 | 66.8/100 | ₹518.90₹519 | ₹12660.10₹12660.10 | 28.40Average 28.4 Average | 20.59%Excellent 20.59% Excellent | 24.80%Excellent 24.80% Excellent | 0.04Excellent 0.0 Excellent | 67.93%Excellent 67.93% Excellent | 34.59%Excellent 34.59% Excellent | 0.38% |
Vimta Labs LtdVimta Labs Ltd... VIMTALABS • 524394 | 65.8/100 | ₹456.70₹457 | ₹2716.50₹2716.50 | 36.39Average 36.4 Average | 19.43%Good 19.43% Good | 25.22%Excellent 25.22% Excellent | 0.02Excellent 0.0 Excellent | 58.03%Excellent 58.03% Excellent | 13.74%Good 13.74% Good | 0.16% |
Take Solutions LtdTake Solutions ... TAKE • 532890 | 19.5/100 | ₹30.93₹31 | ₹481.24₹481.24 | 120.61Average 120.6 Average | 644.12%Excellent 644.12% Excellent | 11.24%Average 11.24% Average | 0.00Excellent 0.0 Excellent | 38.14%Excellent 38.14% Excellent | — — | 0.00% |
Bilcare LtdBilcare Ltd... BI • 526853 | 6.9/100 | ₹62.20₹62 | ₹200.42₹200.42 | — — | -5.58%Poor -5.58% Poor | 1.10%Poor 1.10% Poor | 1.48Average 1.5 Average | 13.81%Good 13.81% Good | -15.48%Poor -15.48% Poor | 0.00% |
NOVELIX PHARMACEUTICALS LIMITENOVELIX PHARMAC... NOVELIX • 536565 | 40.6/100 | ₹57.14₹57 | ₹101.70₹101.70 | 104.85Average 104.8 Average | 0.64%Poor 0.64% Poor | 0.96%Poor 0.96% Poor | 0.00Excellent 0.0 Excellent | -2.33%Poor -2.33% Poor | 82.92%Excellent 82.92% Excellent | 0.00% |
Adeshwar Meditex LtdAdeshwar Medite... ADESHWAR • 543309 | 29.2/100 | ₹18.41₹18 | ₹25.54₹25.54 | 12.34Average 12.3 Average | 5.51%Poor 5.51% Poor | 8.27%Poor 8.27% Poor | 0.16Excellent 0.2 Excellent | -1.36%Poor -1.36% Poor | 8.33%Good 8.33% Good | 0.00% |
Vanta Bioscience LtdVanta Bioscienc... VANTABIO • 540729 | 7.2/100 | ₹24.45₹24 | ₹16.84₹16.84 | — — | -37.24%Poor -37.24% Poor | -11.58%Poor -11.58% Poor | 1.59Average 1.6 Average | — — | -32.27%Poor -32.27% Poor | 0.00% |
Top Healthcare Research, Analytics & Technology Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Syngene International Ltd share price25985.68 Cr
- Indegene Ltd share price12660.10 Cr
- Vimta Labs Ltd share price2716.50 Cr
- Take Solutions Ltd share price481.24 Cr
- Bilcare Ltd share price200.42 Cr
Suven Life Sciences Ltd Quarterly Performance
Latest quarterly metrics for SUVEN — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-64.20%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-55.74%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-12.00%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-24.19%
Compounded annual net profit growth over 5 years
Suven Life Sciences Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SUVEN — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Suven Life Sciences Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Suven Life Sciences Ltd (SUVEN) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Suven Life Sciences Ltd
About SUVEN (Suven Life Sciences Ltd)
Suven Life Sciences Ltd is a pioneering force in the healthcare sector, operating at the intersection of cutting-edge research, advanced analytics, and transformative technology. T...he company dedicates its efforts to unraveling the complexities of neurodegenerative diseases, particularly those affecting the central nervous system. Through rigorous scientific investigation and innovative drug discovery processes, Suven aims to identify and develop novel therapeutic interventions with the potential to significantly improve the lives of patients suffering from conditions like Alzheimer's disease and other neuropsychiatric disorders. Their commitment extends beyond the laboratory, as they actively engage in clinical trials and seek to translate scientific breakthroughs into tangible treatments accessible to patients worldwide. Suven’s approach leverages a blend of sophisticated analytical tools and a deep understanding of disease mechanisms. They meticulously analyze vast datasets to identify potential drug targets and optimize the development of new chemical entities. This data-driven approach, combined with a strong emphasis on intellectual property and strategic partnerships, allows Suven to navigate the challenging landscape of pharmaceutical development with agility and precision. Their research focuses on identifying innovative solutions that address unmet medical needs, striving to provide effective treatments that can slow down disease progression, alleviate symptoms, and ultimately enhance the quality of life for individuals and families affected by debilitating neurological conditions. Driven by a vision of a healthier future, Suven Life Sciences is committed to fostering a culture of scientific excellence and innovation. Their multifaceted operations encompass drug discovery, clinical development, and strategic commercialization planning, all while maintaining a focus on ethical research practices and patient-centered care. By embracing emerging technologies and continually refining their analytical capabilities, Suven positions itself as a dynamic player in the global healthcare arena, working tirelessly to advance the frontiers of neurological disease treatment and contribute to a more hopeful outlook for those affected by these challenging conditions.
Company Details
Key Leadership
Corporate Events
Latest News
SUVEN Share Price: Frequently Asked Questions
What is the current share price of Suven Life Sciences Ltd?
Suven Life Sciences Ltd (SUVEN) trades at ₹262.75 on NSE and BSE. Market cap ₹3.93K (Cr). Educational data only.
What is the P/E ratio of Suven Life Sciences Ltd?
Suven Life Sciences Ltd has a P/E of N/Ax vs industry average 45.95x.
What is the Bull Run score for Suven Life Sciences Ltd?
Suven Life Sciences Ltd has a Bull Run score of 6.5/100 based on 25+ financial parameters.
Does Suven Life Sciences Ltd pay dividends?
Suven Life Sciences Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Suven Life Sciences Ltd?
Suven Life Sciences Ltd has ROE of -87.22%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Suven Life Sciences Ltd?
Suven Life Sciences Ltd has debt-to-equity of 0.00.
Is Suven Life Sciences Ltd a good investment?
Bull Run gives Suven Life Sciences Ltd a score of 6.5/100. This is not investment advice — consult a SEBI-registered advisor.